Upon chart review (KA), participants had not been placed on new medications that affected insulin resistance (metformin, SGLT2 antagonists, GLP1 agonists, hydrochlorothiazide, atypical psychiatric medications) within either the control or intervention group. The gene discussed is SLC5A2; the disease is Insulin resistance.